Spectrum: data confirms tumor selectivity of SPI-1620 in prostate cancer

By Lisa Kerner

Erie, Pa., April 13 - Spectrum Pharmaceuticals, Inc. said new preclinical data showed that SPI-1620, a tumor-selective vasodilator, enhanced the uptake and efficacy of doxorubicin (DOX) in a rat prostate tumor model.

SPI-1620 increased the prostate tumor perfusion by approximately 100% and increased the accumulation of DOX in the tumors by 115%, without affecting other organs.

"This is the second set of significant preclinical data on the success of SPI-1620 in selectively and transiently increasing blood flow to tumors and thus delivery of anticancer agents to those tumors," chairman, chief executive officer and president Rajesh C. Shrotriya said in the release.

"We have now shown enhanced uptake of paclitaxel in breast cancer tumors and doxorubicin in prostate cancer tumors in animal models. We believe SPI-1620 will prove to have a broad range of applications as an adjuvant to chemotherapy in solid tumor treatment."

Officials have discussed the company's development plans with the Food and Drug Administration and plan to file an investigational new drug application later this year.

The information was presented in a poster at the Annual Meeting of the American Association for Cancer Research earlier this month, according to a company news release.

Spectrum Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Irvine, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.